SCHEMBL3070290

SCHEMBL3070290

O=C(O)C(Cl)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
MME P08473 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
ALPG P10696 2/20 0.40
BCL2L1 Q07817 1/20 0.40
BAD Q92934 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11842929 0.94 BCL2L1 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1398583 0.83 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL837009 0.82 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1511329 0.80 HDAC3 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1395758 0.80 HDAC3 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10781537 0.79 AKR1C3 (0.54) LMNAALDH1A1HPGDUSP2CA1
SCHEMBL2454097 0.79 CYP2C9 (0.47) HDAC4HDAC7HDAC5CES2CES1
SCHEMBL3739027 0.79 SRC (0.50) CES2LMNAALDH1A1HPGDHTT
SCHEMBL29009949 0.78 PTGS2 (0.39) LMNAHPGD
SCHEMBL11753976 0.78 CES2 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
EP-0710648-B1 Method for producing oxyindoles KI CHEMICAL INDUSTRY CO LTD (JP) 2002-04-03 EP claimed
US-5679799-A Method for producing oxyindoles K-I CHEMICAL INDUSTRY CO., LTD. (JP) 1997-10-21 US claimed
EP-0710648-A1 Method for producing oxyindoles K I CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-08 EP claimed
EP-4079724-B1 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) 2025-11-12 EP disclosed
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-06-12 US disclosed
US-20250185502-A1 ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT OSRAM OLED GMBH (DE) 2025-06-05 US disclosed
US-12302747-B2 Optoelectronic component, organic functional layer, and method for producing an optoelectronic component OSRAM OLED GMBH (DE) 2025-05-13 US disclosed
EP-4501910-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH Research Co., Ltd. (KR) 2025-02-05 EP disclosed
EP-4193399-B1 ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2025-01-29 EP disclosed
CN-119255981-A Nitrogen-containing heterocyclic compound and use thereof BNH研究有限责任公司 2025-01-03 CN disclosed
EP-3210248-B2 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2024-04-10 EP disclosed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO disclosed
EP-0983507-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES Trega Biosciences, Inc. (US) 2000-03-08 EP disclosed
EP-0977989-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2000-02-09 EP disclosed
US-5925527-A SCREENING NEW PHARMACEUTICALS TREGA BIOSCIENCES, INC. (US) 1999-07-20 US disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998034111-A1 TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
US-5679799-A Method for producing oxyindoles K-I CHEMICAL INDUSTRY CO., LTD. (JP) 1997-10-21 US disclosed
EP-0710648-A1 Method for producing oxyindoles K I CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF NLN, GRIN1, GRIN2A HDAC3 820/4885HDAC4 1150/4885HDAC1 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.